COVID-19 vaccine maker Vaxart Fraud Investigation Underway

 

Vaxart based in California has been working on a Covid-19 vaccine. The company is being sued because investors the old company is exaggerating its partnership with the US government Operation Warp Speed program for developing COVID-19 vaccines and treatments for the disease.

In a press release Vaxart (VXRT) issued, the company statement said,  “Vaxart’s Covid-19 Vaccine Selected for the US Government’s Operation Warp Speed.” after the announcement the stock jump up $17.00 per share from $3 per share. According to SEC filings that is a $200 million profit.  Armistice, which has two execs on Vaxart’s board—including its founder, Stephen Boyd—immediately sold all its warrants. “Armistice sold 27.6 million Vaxart shares, reducing its overall beneficial ownership in Vaxart from 29% to 0.2%, reaping profits of approximately $200 million,” one complaint said.

One of the lawsuits stated in the complaint  that Vaxart violated securities laws by misleading statements that it was a major player in Operation Warp Speed,

The US Department of Health and Human Services (HHS) told the New York Times that it had not entered into a funding agreement or negotiations with Vaxart. Source NYT

Federal prosecutors will be looking at different lawsuits against the company, its board members and executives.

You can view the SEC filing here –https://www.sec.gov/Archives/edgar/data/0000072444/000143774920021115/vxrt20201013_8k.htm

Vaxart based in California has been working on a Covid-19 vaccine. The company is being sued because investors the old company is exaggerating its partnership with the US government Operation Warp Speed program for developing COVID-19 vaccines and treatments for the disease.

In a press release Vaxart (VXRT) issued, the company statement said,  “Vaxart’s Covid-19 Vaccine Selected for the US Government’s Operation Warp Speed.” after the announcement the stock jump up $17.00 per share from $3 per share. According to SEC filings that is a $200 million profit.  Armistice, which has two execs on Vaxart’s board—including its founder, Stephen Boyd—immediately sold all its warrants. “Armistice sold 27.6 million Vaxart shares, reducing its overall beneficial ownership in Vaxart from 29% to 0.2%, reaping profits of approximately $200 million,” one complaint said.

 

Jay Z- launches $300 Earbuds Competing with Apple Air Pods Pro

One of the lawsuits stated in the complaint  that Vaxart violated securities laws by misleading statements that it was a major player in Operation Warp Speed.

The US Department of Health and Human Services (HHS) told the New York Times that it had not entered into a funding agreement or negotiations with Vaxart. Source NYT

Federal prosecutors will be looking at different lawsuits against the company, its board members and executives.

https://www.sec.gov/Archives/edgar/data/0000072444/000143774920021115/vxrt20201013_8k.htm


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.